Latest news
NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 12:46:24 GMTNewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingViewTradingView · Wed, 05 Aug 2026 11:13:00 GMTNewAmsterdam Pharma Co N.V. Q2 2026: Revenue $3.7M, EPS $(0.52) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 11:11:01 GMT